middle.news
Patrys Secures Ethics Approval for Phase 1A Trial of RLS-2202 with Dosing Set for Q3
8:12am on Friday 28th of August, 2026 AEST
•
Healthcare
Read Story
Patrys Secures Ethics Approval for Phase 1A Trial of RLS-2202 with Dosing Set for Q3
8:12am on Friday 28th of August, 2026 AEST
Key Points
HREC approval obtained for Phase 1A trial of RLS-2202
Trial to assess safety, tolerability, and pharmacokinetics in healthy volunteers
Clinical site activation and participant recruitment underway at CMAX
First dosing expected within the current quarter
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Patrys (ASX:PAB)
OPEN ARTICLE